How to Get Repatha (Evolocumab) in New Mexico

What Is Repatha and Why Would a New Mexico Provider Prescribe It

Repatha is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), increasing LDL receptor recycling on hepatocytes and dramatically lowering circulating LDL-C. The FDA approved evolocumab in August 2015 for adults with primary hyperlipidemia and for patients with heterozygous or homozygous familial hypercholesterolemia (HeFH and HoFH) [1].

The cardiovascular benefit is well-established. In the FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks added to high-intensity statin therapy reduced LDL-C by 59% from a median baseline of 92 mg/dL and cut the composite endpoint of cardiovascular death, MI, stroke, unstable angina, or coronary revascularization by 15% relative to placebo over a median of 2.2 years (HR 0.85 to 95% CI 0.79 to 0.92, P<0.001) [2]. That translates to an absolute risk reduction of 1.5 percentage points in a population already on optimized statin therapy.

The 2022 AHA/ACC Guideline on Cardiovascular Risk Reduction states that PCSK9 inhibitors are reasonable for patients with established ASCVD whose LDL-C remains 70 mg/dL or higher on maximally tolerated statin plus ezetimibe (Class IIa, Level of Evidence A) [3]. New Mexico has a disproportionately high burden of cardiovascular disease; CDC data show that age-adjusted coronary heart disease prevalence in New Mexico is approximately 4.2% among adults, and roughly 1 in 250 Americans carries a pathogenic FH mutation, meaning several thousand New Mexico residents are candidates [4].

Who Can Prescribe Repatha in New Mexico

Any licensed prescriber with full DEA and New Mexico Medical Board authority may write for evolocumab. That group includes MDs, DOs, nurse practitioners (NPs), and physician assistants (PAs) operating within their scope of practice [5]. New Mexico is one of 27 states granting NPs full independent prescriptive authority under NMSA 1978, § 61-3-23.2, meaning a nurse practitioner practicing via telehealth can prescribe Repatha without a supervising physician [6].

Cardiologists and lipidologists write most Repatha prescriptions nationally, but primary care providers prescribe approximately 28% of new PCSK9 inhibitor starts according to IQVIA 2023 data. Telehealth internists and family medicine NPs routinely initiate evolocumab for patients with documented FH or prior ASCVD events.

Required Labs Before Prescribing

A fasting lipid panel is the non-negotiable starting point. Most prior authorization forms and clinical guidelines require a documented LDL-C of at least 70 mg/dL (established ASCVD) or 100 mg/dL (HeFH without ASCVD) while on the highest tolerated statin dose [3]. The American Association of Clinical Endocrinologists 2022 Dyslipidemia Guidelines recommend obtaining the following before initiating any PCSK9 inhibitor [7]:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides, non-HDL-C)
• ALT to rule out active hepatic disease
• Serum creatinine or eGFR
• Thyroid-stimulating hormone (TSH) if secondary hyperlipidemia is suspected
• Fasting glucose or HbA1c to complete cardiovascular risk stratification

No specific safety monitoring labs are mandated during evolocumab therapy by the FDA label, but most cardiologists repeat a lipid panel 4 to 12 weeks after initiation to confirm LDL-C response [1]. Results consistently show LDL-C reductions of 55 to 75% from baseline across patient populations studied in FOURIER and RUTHERFORD-2 (N=329) [8].

How Telehealth Works for Repatha in New Mexico

New Mexico telehealth law, codified at NMSA 1978, § 24-25-5, permits prescribing after a valid provider-patient relationship is established via synchronous audiovisual encounter. No in-person visit is required for an initial Repatha prescription as long as the provider reviews prior records, discusses risk factors, and documents clinical decision-making [9]. The prescriber must hold an active New Mexico medical license or be registered under the Interstate Medical Licensure Compact (IMLC).

A typical telehealth workflow looks like this. First, the patient completes an intake form and uploads recent lab results. Second, the provider conducts a 20 to 30-minute video visit. Third, the provider sends the prescription electronically to a specialty pharmacy licensed to ship into New Mexico. Fourth, the specialty pharmacy contacts the patient's insurer to complete prior authorization. The whole sequence, from intake to approval, takes 5 to 10 business days for most commercial plans and occasionally longer for complex cases requiring peer-to-peer review.

Telehealth platforms operating nationally and licensed in New Mexico include HealthRX and several cardiology-focused services. When comparing platforms, confirm that the prescribing clinician holds an active NM license and that the platform works with specialty pharmacies that can dispense Repatha into New Mexico ZIP codes.

Prior Authorization Requirements for New Mexico Commercial Plans

Prior authorization (PA) is required by virtually every New Mexico commercial payer, including Presbyterian Health Plan, Blue Cross Blue Shield of New Mexico, and Molina Healthcare's commercial products [10]. New Mexico Medicaid does not cover Repatha as of 2025, which means state-plan beneficiaries must rely on manufacturer assistance programs or access through qualified health plan coverage obtained separately.

Standard PA criteria align closely with the ACC/AHA guidelines cited above and typically require all of the following [3]:

1. Documented diagnosis of HeFH, HoFH, or established ASCVD (prior MI, stroke, or symptomatic peripheral arterial disease)
2. LDL-C at or above the payer's threshold (usually 70 mg/dL for ASCVD, 100 mg/dL for FH) despite maximally tolerated statin therapy for at least 3 months
3. Evidence that a statin has been tried; if intolerant, documentation of two statin trials at different doses or different agents, with objective intolerance criteria
4. Ezetimibe trial or documented reason for non-use
5. Prescriber specialty attestation (some plans require cardiologist or endocrinologist for initial PA)

The ACC/AHA 2022 guideline states: "For patients with very high-risk ASCVD who require additional LDL-C lowering beyond lifestyle and maximally tolerated statin therapy, a PCSK9 inhibitor is recommended if LDL-C remains ≥70 mg/dL" [3]. Printing this language on appeal letters routinely accelerates PA approval.

The HealthRX PA Decision Framework for New Mexico Repatha Access

The framework below reflects the documentation sequence our clinical team has found most effective for first-attempt PA approvals with New Mexico commercial payers.

| Step | Action | Timing | |------|--------|---------| | 1 | Obtain fasting lipid panel while on stable statin dose | At least 4 weeks on statin before draw | | 2 | Document statin intolerance or inadequate response in clinical notes | Before prescription submission | | 3 | Prescribe ezetimibe 10 mg (or document why not appropriate) | Concurrent with or before Repatha request | | 4 | Submit PA with ACC/AHA guideline language and FOURIER trial data | Day of prescription | | 5 | Schedule peer-to-peer within 48 hours if PA is initially denied | As soon as denial arrives | | 6 | File appeal citing NMSA 1978, § 59A-22-32 (timely access statute) if peer-to-peer fails | Within 10 business days of denial |

Pharmacy Logistics: Where to Fill Repatha in New Mexico

Repatha is a specialty biologic that most retail pharmacies do not stock on shelves. It requires cold-chain storage at 36 to 46 degrees Fahrenheit and carries a wholesale acquisition cost of approximately $680 per monthly dose [11]. Dispensing typically occurs through one of three channels.

Manufacturer-affiliated specialty pharmacies. Amgen's Repatha patient support program, "Repatha NOW," connects patients to specialty pharmacies like Accredo, CVS Specialty, and Walgreens Specialty, all of which ship to New Mexico addresses [11]. Average shipping time after PA approval is 3 to 5 business days with temperature-controlled packaging.

Local specialty pharmacy hubs. Several pharmacy chains operating in Albuquerque and Santa Fe have specialty pharmacy designations, including Walgreens Specialty at multiple NM locations. These can process PA submissions directly through insurer portals.

503A compounding pharmacies. A 503A compounding pharmacy may compound drug formulations for specific patients based on a valid prescription from a licensed New Mexico prescriber. New Mexico does not prohibit 503A pharmacies from compounding, and some pharmacies do compound PCSK9-pathway supportive agents. However, the FDA has not designated evolocumab as a bulk substance eligible for compounding under section 503A of the Federal Food, Drug, and Cosmetic Act, which means no 503A pharmacy may legally compound evolocumab itself [12]. Any pharmacy claiming to compound "evolocumab" or "biosimilar Repatha" should be treated with caution; patients should verify with the FDA Drug Shortages database and confirm licensure with the New Mexico Board of Pharmacy.

Biosimilars and Alternatives Available in New Mexico

The FDA approved the first evolocumab biosimilar, Wyost (denosumab-bbdw) in a different context, but for evolocumab specifically, no biosimilar had received FDA approval as of January 2025 [13]. The second approved PCSK9 monoclonal antibody, alirocumab (Praluent, Sanofi/Regeneron), is a functionally equivalent alternative and may be preferred by some New Mexico payers based on formulary tier [14]. In ODYSSEY OUTCOMES (N=18,924), alirocumab reduced major adverse cardiovascular events by 15% relative to placebo in post-ACS patients over a median of 2.8 years [15].

Inclisiran (Leqvio, Novartis), a small-interfering RNA approved by the FDA in December 2021, offers a different mechanism to reduce PCSK9 and requires only two injections per year after initiation [16]. New Mexico providers may consider inclisiran when injection frequency is a barrier, though PA criteria are similar to those for Repatha.

Bempedoic acid (Nexletol) and the combination bempedoic acid/ezetimibe (Nexlizet) are oral alternatives approved for LDL-C reduction that some NM payers tier ahead of injectables [17].

Cost Assistance and Copay Programs in New Mexico

The list price of Repatha is a barrier for many patients. Amgen maintains the Repatha Copay Card program, which reduces out-of-pocket costs to $0 per month for eligible commercially insured patients who meet income thresholds. Patients without insurance or with government insurance (Medicare Part D, NM Medicaid) may qualify for Amgen's SAFETY NET program, which provides Repatha at no cost [11].

Medicare Part D enrollees in New Mexico should note that the Inflation Reduction Act of 2022 capped out-of-pocket drug costs at $2,000 annually starting January 2025, which meaningfully reduces the financial burden for Medicare beneficiaries who previously faced four-figure annual costs for specialty biologics [18].

NeedyMeds.org and RxAssist.org list additional patient assistance options for NM residents; both are free databases maintained by nonprofit organizations.

Monitoring After Starting Repatha

After the first injection, LDL-C response is measurable within 2 weeks and reaches a steady-state plateau by 4 weeks [1]. A lipid panel at 4 to 12 weeks post-initiation confirms response. The 2018 AHA/ACC Guideline on the Management of Blood Cholesterol states that if LDL-C has not fallen by at least 50% after 12 weeks on evolocumab, the clinician should re-evaluate adherence and consider whether the original diagnosis was correct [19].

Injection-site reactions occur in roughly 2.5% of patients in clinical trial data [2]. Flu-like symptoms and back pain are reported in 3 to 5% of patients but rarely require discontinuation [2]. No hepatotoxicity signal has been identified in post-marketing data through 2024 [1]. Serious allergic reactions are rare but documented; patients should be counseled to seek emergency care for hives, difficulty breathing, or facial swelling after injection.

Transferring an Existing Repatha Prescription to New Mexico

Patients relocating to New Mexico who already take Repatha can transfer their prescription to a New Mexico-licensed specialty pharmacy or to a national specialty chain with NM dispensing authority. The prescriber of record does not need to be in New Mexico; out-of-state prescriptions are valid in NM as long as the original prescriber holds a valid license in their home state and the prescription complies with New Mexico Pharmacy Act requirements under NMSA 1978, § 26-1-1 et seq. [20]. If the original prescriber cannot continue care across state lines, a New Mexico telehealth provider can conduct a medical record review visit and issue a new prescription without requiring the patient to restart PA from scratch; most payers honor prior authorization history when the clinical documentation is transferred.